SWEEKLY NEWSLETTER Issue 15 | 12 - 16 April

Article Sharing Prof. Ren-He XU's Stem Cell Research Promotes Fat Engraftment after Transplantation

FACULTY

OF HEALTH

SCIENCES

Prof. Ren-He Xu and his research team have discovered a new way to enhance fat engraftment with the use of mesenchymal stromal cells (MSCs) derived from human embryonic stem cells (hESCs). This type of MSCs has the potential to be used as an innovative, cellbased biomaterial to support lipofilling widely used in cosmetic surgery. The related research finding has been published in the internationally renowned journal *Biomaterials*.

Autologous fat grafting has been widely used in cosmetic surgery for reconstructing facial and body parts after cancer surgery, in treating scars and wrinkles, and in breast enhancement. However, the graft survival rate varies dramatically between 25% and 90% because fat tissues become necrotic and fibrotic due to lack of blood supply. It has been known that MSCs isolated from somatic tissues such as adipose, bone marrow, and umbilical cord can increase the survival of transplanted tissues by promoting vascularisation and regeneration. However, somatic tissue-derived MSCs rely on donations and the process carries the risk of transmitting potential pathogens or genetically mutated cells. Although isolation of MSCs from autologous tissues is free of this problem, there is only a limited number of autologous MSCs available. In contrast, hESCs are an unlimited source with reliable and consistent quality and hESC-derived MSCs can be a better substitute for somatic MSCs.



The use of MSCs enhances fat engraftment.

Prof Xu's team has demonstrated through multiple animal disease models that MSCs derived from hESCs via a trophoblast stage (T-MSCTM) have significant therapeutic effects in mice and/or monkeys with multiple sclerosis, colitis, and osteoarthritis. They also promote wound healing in both wild-type and diabetic mice. T-MSCs are patented in both the United States and China, and preclinical studies have been completed on their pharmacodynamics and biosafety in animals. Last year, the US Food and Drug Administration approved T-MSCs as an Investigational New Drug (IND) for clinical trials on multiple sclerosis.

In this study, Prof Xu's team has found that T-MSCs enhance fat graft survival and retain graft weight comparable to the stromal vascular fraction (SVF) or MSCs derived from fat tissues which are the techniques currently used in clinics to improve fat engraftment. The team has also found that T-MSCs help glue dissociated fat tissues to form a capsulated graft within as early as 24 hours of transplantation and facilitate graft remodelling by forming new blood vessels and adipocyte regeneration. A patent application has been filed in both China

FACULTY
OF HEALTH
SCIENCESSWEEKLY
SWEEKLY
SUBJECTER
Issue 15 | 12 - 16 April

and the US on the novel utilisation of T-MSCs.



This type of MSCs has the potential to be used as an innovative, cell-based biomaterial to support lipofilling widely

used in cosmetic surgery.

Prof Xu is the corresponding author of the study entitled 'Human ESC-derived MSCs Enhance Fat Engraftment by Promoting Adipocyte Reaggregation, Secreting CCL2 and Mobilizing Macrophages'. The study was led by Prof Xu, with the contributions of his PhD students Roma Borkar and Dejin ZHENG, postdoctoral fellow Xiaoyan WANG, and research assistant Dr. Enqin LI. Zhengqiang MIAO, a student of Prof. Chris WONG, provided bioinformatic analysis. This project was funded by Macau Science and Technology Development Fund (grant number: 095/2017/A1 and 0112/2018/A3), UM Research Committee funds (grant number: MYRG-2016-00070-FHS, MYRG-2017-00124-FHS, and CPG-2021-00031-FHS), and FDCT-National Natural Science Foundation of China joint grant (grant number: 0008/2019/AFJ).



2 Community Story Dr. Jung Woo PARK Shares COVID-19 Talk in UM CKPC

In the inspiring seminar of the UM Chao Kuang Piu College on 14 April, Dr. Jung Woo PARK presented a talk on "Vaccines of COVID-19: What, Why, and How" to the college students.







SWEEKLY NEWSLETTER Issue 15 | 12 - 16 April



FACULT

SCIENCES

OF HEAI

FHS Postdoc Student Seminar

Presented by Prof. Kin TAM's group

On 15 April, Ms. Yan ZHOU and Ms. Yizhen GUO of Prof. Kin TAM's group presented "Targeting Aberrant Glucose Metabolism in NSCLC" and "Pharmaceutical Evaluation of New Compounds Inhibiting Pyruvate Dehydrogenase Kinase 1" respectively.

The next seminar will be held on 29 April, and presented by the group members of Prof. Leo LEE and Prof. Joong Sup SHIM.









UPCOMING EVENTS

April		
Mon	19 <u>Qualifying Examination</u> Speaker:Meilin WANG Supervisor: Prof. William CHAO Time: 10:00 Venue: E12-4004	26 <u>Qualifying Examination</u> Speaker: Aiping ZHANG Supervisor: Prof. Chuxia DENG Time: 9:00 Venue: E12-4004 <u>Qualifying Examination</u> Speaker: Tingting AN Supervisor: Prof. Xiaoling XU Time:10:45 Venue: E12-4004
Tue	20	27
Wed	21 <u>Qualifying Examination</u> Speaker: Mengze XU Supervisor: Prof. Zhen YUAN Time: 14:30 Venue: E12-4004 <u>BCAT Meeting</u> Speaker: Prof.Ren-He XU Time: 17:00-18:00	28 <u>Qualifying Examination</u> Speaker: Dan ZHANG Supervisor: Prof. Xuanjun ZHANG Time: 10:15 Venue: E12-3036 <u>Oral Defence</u> Wen LI Supervisor: Prof. Yutao XIANG
	Venue: E12-G004	Time: 13:00 Venue: E12-1015 Oral Defence Yuan YANG Supervisor: Prof. Yutao XIANG Time: 15:00 Venue: E12-1015 BCAT Meeting Speaker: Dr. Qiang CHEN Time: 17:00-18:00 Venue: E12-G004
Thu	22	29 Qualifying Examination Speaker: Wenxi LI Supervisor: Prof. Yunlu DAI Time: 14:00 Venue: E12-4004 Qualifying Examination Speaker: Guohao WANG Supervisor: Prof. Yunlu DAI Time: 16:00 Venue: E12-4004 FHS Postdoc/ Student Seminar Session: Cancer Research Host: Prof. Leo LEE and Prof. Joong Sup SHIM Time: 17:00-18:00 Venue: N22-G002 and Zoom
Fri	23	30

For more information or submission of articles to be featured, please contact Ms. Mathilde CHEANG at mathildec@um.edu.mo or 8822 4909.